Glutamate-based therapeutic approaches: Clinical trials with NMDA antagonists

Current Opinion in Pharmacology

Volumn 6, Issue 1 SPEC. ISS., 2006, Pages 53-60

  Muir, Keith W ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 PHOSPHONOALLYL) 2 PIPERAZINECARBOXYLIC ACID; 4 PHOSPHONOMETHYLPIPECOLIC ACID; 4,6 DICHLORO 3 (2 OXO 1 PHENYL 3 PYRROLIDINYLIDENEMETHYL) 1H INDOLE 2 CARBOXYLIC ACID; ACETYLSALICYLIC ACID; AMANTADINE; ANTICONVULSIVE AGENT; APTIGANEL; CHOLINESTERASE INHIBITOR; DEXANABINOL; DEXTROMETHORPHAN; DIZOCILPINE; EAA 494; ELIPRODIL; GAVESTINEL; GLUTAMIC ACID; KETAMINE; LANICEMINE; MAGNESIUM; MEMANTINE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; PLACEBO; REMACEMIDE; TRAXOPRODIL;

AGITATION; ALZHEIMER DISEASE; BRAIN EDEMA; BRAIN INJURY; CATATONIA; CLINICAL TRIAL; COORDINATION DISORDER; DEMENTIA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG STRUCTURE; DYSARTHRIA; DYSKINESIA; EPILEPSY; EXCITOTOXICITY; FATIGUE; HALLUCINATION; HUMAN; HUNTINGTON CHOREA; HYPERTENSION; HYPOTHERMIA; MULTIINFARCT DEMENTIA; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; PHANTOM PAIN; PRIORITY JOURNAL; REVIEW; SENSORY DYSFUNCTION; SIDE EFFECT; STROKE; SUBARACHNOID HEMORRHAGE; SYSTEMATIC REVIEW; TREATMENT FAILURE;

EID: 30844439634     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2005.12.002     Document Type: Review

References (58)

1. S.M. Rothman J.W. Olney Glutamate and the pathophysiology of hypoxic-ischemic brain damage Ann Neurol 19 1986 105-111
2. S.A. Lipton P.A. Rosenberg Mechanisms of disease: Excitatory amino acids as a final common pathway for neurologic disorders N Engl J Med 330 1994 613-622
3. L.V. Metman S. Konitsiotis T.N. Chase Pathophysiology of motor response complications in Parkinson's disease: Hypotheses on the why, where, and what Mov Disord 15 2000 3-8
4. K.W. Muir K.R. Lees Clinical experience with excitatory amino acid antagonist drugs Stroke 26 1995 503-513
5. C.K. Park D.G. Nehls D.I. Graham G.M. Teasdale J. McCulloch The glutamate antagonist MK-801 reduces focal ischemic brain damage in the rat Ann Neurol 24 1988 543-551
6. J. McCulloch Excitatory amino acid antagonists and their potential for the treatment of ischaemic brain damage in man Br J Clin Pharmacol 34 1992 106-114
7. M.R. Macleod T. O'Collins D.W. Howells G.A. Donnan Pooling of animal experimental data reveals influence of study design and publication bias Stroke 35 2004 1203-1208
8. M. Kaste Use of animal models has not contributed to development of acute stroke therapies. Pro Stroke 36 2005 2323-2324
9. M. Fisher T. Tatlisumak Use of animal models has not contributed to development of acute stroke therapies. Con Stroke 36 2005 2324-2325
10. M. Fisher G.W. Albers G.A. Donnan A.J. Furlan J.C. Grotta C.S. Kidwell R.L. Sacco L.R. Wechsler Enhancing the development and approval of acute stroke therapies: Stroke therapy academic industry roundtable Stroke 36 2005 1808-1813
11. K.W. Muir K.R. Lees Excitatory amino acid antagonists for acute stroke Cochrane Database Syst Rev 2003 CD001244
12. H.C. Diener A. AlKhedr O. Busse W. Hacke P.H. Zingmark N. Jonsson H. Basun Treatment of acute ischaemic stroke with the low-affinity, use-dependent NMDA antagonist AR-R15896AR. A safety and tolerability study J Neurol 249 2002 561-568
13. S.M. Davis K.R. Lees G.W. Albers H.C. Diener S. Markabi G. Karlsson J. Norris Selfotel in acute ischemic stroke: Possible neurotoxic effects of an NMDA antagonist Stroke 31 2000 347-354
14. G.W. Albers L.B. Goldstein D. Hall L.M. Lesko Aptiganel hydrochloride in acute ischemic stroke: A randomized controlled trial JAMA 286 2001 2673-2682
15. R.L. Sacco J.T. DeRosa E.C. Haley Jr. B. Levin P. Ordronneau S.J. Phillips T. Rundek R.G. Snipes J.L. Thompson Glycine antagonist in neuroprotAction for patients with acute stroke: GAIN Americas: a randomized controlled trial JAMA 285 2001 1719-1728
16. K.R. Lees K. Asplund A. Carolei S.M. Davis H.C. Diener M. Kaste J.M. Orgogozo J. Whitehead Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: A randomised controlled trial. GAIN International Investigators Lancet 355 2000 1949-1954
17. E.C. Haley Jr. J.L. Thompson B. Levin S. Davis K.R. Lees J.G. Pittman J.T. DeRosa P. Ordronneau D.L. Brown R.L. Sacco Gavestinel does not improve outcome after acute intracerebral hemorrhage: An analysis from the GAIN International and GAIN Americas studies Stroke 36 2005 1006-1010
18. C. Ikonomidou L. Turski Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol 1 2002 383-386
19. J.W. McDonald F.S. Silverstein M.V. Johnston Magnesium reduces N-methyl-D-aspartate (NMDA)-mediated brain injury in perinatal rats Neurosci Lett 109 1990 234-238
20. K.W. Muir K.R. Lees I. Ford S. Davis Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): Randomised controlled trial Lancet 363 2004 439-445
21. J.L. Saver C. Kidwell M. Eckstein S. Starkman Prehospital neuroprotective therapy for acute stroke: Results of the Field Administration of Stroke Therapy-Magnesium (FAST-MAG) pilot trial Stroke 35 2004 e106-e108
22. W.M. van den Bergh A. Algra F. Van Kooten C.M. Dirven J. van Gijn M. Vermeulen G.J. Rinkel Magnesium sulfate in aneurysmal subarachnoid hemorrhage: A randomized controlled trial Stroke 36 2005 1011-1015
23. C. Willis S. Lybrand N. Bellamy Excitatory amino acid inhibitors for traumatic brain injury Cochrane Database Syst Rev 2004 CD003986
24. G.F. Morris R. Bullock S.B. Marshall A. Marmarou A. Maas L.F. Marshall Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: Results of two phase III clinical trials. The Selfotel Investigators J Neurosurg 91 1999 737-743
25. N. Knoller L. Levi I. Shoshan E. Reichenthal N. Razon Z.H. Rappaport A. Biegon Dexanabinol (HU-211) in the treatment of severe closed head injury: A randomized, placebo-controlled, phase II clinical trial Crit Care Med 30 2002 548-554
26. M.R. Bullock R.E. Merchant C.A. Carmack E. Doppenberg A.K. Shah K.D. Wilner G. Ko S.A. Williams An open-label study of CP-101,606 in subjects with a severe traumatic head injury or spontaneous intracerebral hemorrhage Ann N Y Acad Sci 890 1999 51-58
27. R.E. Merchant M.R. Bullock C.A. Carmack A.K. Shah K.D. Wilner G. Ko S.A. Williams A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury Ann N Y Acad Sci 890 1999 42-50
28. S.A. Areosa F. Sherriff R. McShane Memantine for dementia Cochrane Database Syst Rev 2005 CD003154
29. B. Reisberg R. Doody A. Stoffler F. Schmitt S. Ferris H.J. Mobius Memantine in moderate-to-severe Alzheimer's disease N Engl J Med 348 2003 1333-1341
30. P.N. Tariot M.R. Farlow G.T. Grossberg S.M. Graham S. McDonald I. Gergel Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial JAMA 291 2004 317-324
31. G. Wilcock H.J. Mobius A. Stoffler A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500) Int Clin Psychopharmacol 17 2002 297-305
32. J.M. Orgogozo A.S. Rigaud A. Stoffler H.J. Mobius F. Forette Efficacy and safety of memantine in patients with mild to moderate vascular dementia: A randomized, placebo-controlled trial (MMM 300) Stroke 33 2002 1834-1839
33. A. Beister P. Kraus W. Kuhn M. Dose A. Weindl M. Gerlach The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease J Neural Transm Suppl 111 2004 S117-S122
34. M.K. Magnet R.M. Bonelli H.P. Kapfhammer Amantadine in the akinetic-rigid variant of Huntington's disease Ann Pharmacother 38 2004 1194-1196
35. L. Verhagen Metman M.J. Morris C. Farmer M. Gillespie K. Mosby J. Wuu T.N. Chase Huntington's disease: A randomized, controlled trial using the NMDA-antagonist amantadine Neurology 59 2002 694-699
36. K. Kieburtz A. Feigin M. McDermott P. Como D. Abwender C. Zimmerman C. Hickey C. Orme K. Claude J. Sotack A controlled trial of remacemide hydrochloride in Huntington's disease Mov Disord 11 1996 273-277
37. C. Lucetti P. Del Dotto G. Gambaccini G. Dell' Agnello S. Bernardini G. Rossi L. Murri U. Bonuccelli IV amantadine improves chorea in Huntington's disease: An acute randomized, controlled study Neurology 60 2003 1995-1997
38. F.O. Walker V.P. Hunt An open label trial of dextromethorphan in Huntington's disease Clin Neuropharmacol 12 1989 322-330
39. A. Richens G. Mawer P. Crawford B. Harrison A placebo-controlled, double-blind cross-over trial of adjunctive one month remacemide hydrochloride treatment in patients with refractory epilepsy Seizure 9 2000 537-543
40. D.W. Chadwick T.A. Betts H.G. Boddie P.M. Crawford P. Lindstrom P.K. Newman I. Soryal S. Wroe T.A. Holdich Remacemide hydrochloride as an add-on therapy in epilepsy: A randomized, placebo-controlled trial of three dose levels (300, 600 and 1200 mg/day) in a Q.I.D. regimen Seizure 11 2002 114-123
41. M.W. Jones W.T. Blume A. Guberman M.A. Lee N. Pillay D.F. Weaver F. Veloso T.A. Holdich Remacemide hydrochloride as an add-on therapy in epilepsy: A randomized, placebo-controlled trial of three dose levels (300, 600 and 800 mg/day) in a B.I.D. regimen Seizure 11 2002 104-113
42. J.P. Leach A.G. Marson J.L. Hutton Remacemide for drug-resistant localization related epilepsy Cochrane Database Syst Rev 2002 CD001900
43. N. Crosby K.H. Deane C.E. Clarke Amantadine in Parkinson's disease Cochrane Database Syst Rev 2003 CD003468
44. N.J. Crosby K.H. Deane C.E. Clarke Amantadine for dyskinesia in Parkinson's disease Cochrane Database Syst Rev 2003 CD003467
45. A. Thomas D. Iacono A.L. Luciano K. Armellino A. Di Iorio M. Onofrj Duration of amantadine benefit on dyskinesia of severe Parkinson's disease J Neurol Neurosurg Psychiatry 75 2004 141-143
46. C.E. Clarke J.A. Cooper T.A. Holdich A randomized, double-blind, placebo-controlled, ascending-dose tolerability and safety study of remacemide as adjuvant therapy in Parkinson's disease with response fluctuations Clin Neuropharmacol 24 2001 133-138
47. I. Shoulson J. Penney M. McDermott S. Schwid E. Kayson T. Chase S. Fahn J.T. Greenamyre A. Lang A. Siderowf A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease Neurology 56 2001 455-462
48. C. Taus G. Giuliani E. Pucci R. D'Amico A. Solari Amantadine for fatigue in multiple sclerosis Cochrane Database Syst Rev 2003 CD002818
49. N. Elia M.R. Tramer Ketamine and postoperative pain - a quantitative systematic review of randomised trials Pain 113 2005 61-70
50. C.J. McCartney A. Sinha J. Katz A qualitative systematic review of the role of N-methyl-D-aspartate receptor antagonists in preventive analgesia Anesth Anal 98 2004 1385-4000
51. P. Amin N.D. Sturrock A pilot study of the beneficial effects of amantadine in the treatment of painful diabetic peripheral neuropathy Diabet Med 20 2003 114-118
52. K.A. Nelson K.M. Park E. Robinovitz C. Tsigos M.B. Max High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia Neurology 48 1997 1212-1218
53. K. Wiech R.T. Kiefer S. Topfner H. Preissl C. Braun K. Unertl H. Flor N. Birbaumer A placebo-controlled randomized crossover trial of the N-methyl-D-aspartic acid receptor antagonist, memantine, in patients with chronic phantom limb pain Anesth Analg 98 2004 408-413
54. C. Maier R. Dertwinkel N. Mansourian I. Hosbach P. Schwenkreis I. Senne G. Skipka M. Zenz M. Tegenthoff Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain-results of a randomized double-blinded, placebo-controlled trial Pain 103 2003 277-283
55. L. Nikolajsen H. Gottrup A.G. Kristensen T.S. Jensen Memantine (a N-methyl-D-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: A randomized, double-blinded, cross-over study Anesth Analg 91 2000 960-966
56. B.S. Galer D. Lee T. Ma B. Nagle T.G. Schlagheck MorphiDex (morphine sulfate/dextromethorphan hydrobromide combination) in the treatment of chronic pain: Three multicenter, randomized, double-blind, controlled clinical trials fail to demonstrate enhanced opioid analgesia or reduction in tolerance Pain 115 2005 284-295
57. K.C. Carlsson N.O. Hoem E.R. Moberg L.C. Mathisen Analgesic effect of dextromethorphan in neuropathic pain Acta Anaesthesiol Scand 48 2004 328-336
58. M.S. Wallace M.C. Rowbotham N.P. Katz R.H. Dworkin R.M. Dotson B.S. Galer R.L. Rauck M.M. Backonja S.N. Quessy P.D. Meisner A randomized, double-blind, placebo-controlled trial of a glycine antagonist in neuropathic pain Neurology 59 2002 1694-1700